Clinical trials
Hyperlipoproteinemia Type II trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 4 |
| Unknown status | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amgen | 4 |
| Fundación Hipercolesterolemia Familiar | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Novartis Pharmaceuticals | 2 |
| AstraZeneca | 1 |
| Ferrer Internacional S.A. | 1 |
| Institut Investigacio Sanitaria Pere Virgili | 1 |
| Instituto Aragones de Ciencias de la Salud | 1 |
| NewAmsterdam Pharma | 1 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipoproteinemia Type II | 17 |
| Hypercholesterolemia | 8 |
| Homozygous Familial Hypercholesterolemia | 5 |
| Cardiovascular Diseases | 3 |
| Aortic Valve Stenosis | 2 |
| Dyslipidemias | 2 |
| Genetic Diseases, Inborn | 2 |
| Arteriosclerosis | 1 |
| Heart Failure | 1 |
| Hyperlipidemias | 1 |
Trials
Showing 26 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.